Tag Archives: Second-Line Treatment

GSK’s Belantamab Mafodotin Shows Promise as Second-Line Treatment for Multiple Myeloma in Phase III Trial

Posted on 27, November 2023 by

(IN BRIEF) GlaxoSmithKline (GSK) has reported positive results from the interim efficacy analysis of the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial successfully met its primary endpoint of … Read the full press release →

Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom

Tagged , , , , , , ,